Charles M. Baum
2018
In 2018, Charles M. Baum earned a total compensation of $4.9M as President and Chief Executive Officer at Mirati Therapeutics, a 200% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $434,800 |
|---|---|
| Option Awards | $3,851,079 |
| Salary | $579,700 |
| Other | $2,500 |
| Total | $4,868,079 |
Baum received $3.9M in option awards, accounting for 79% of the total pay in 2018.
Baum also received $434.8K in non-equity incentive plan, $579.7K in salary and $2.5K in other compensation.
Rankings
In 2018, Charles M. Baum's compensation ranked 2,089th out of 14,244 executives tracked by ExecPay. In other words, Baum earned more than 85.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,089 out of 14,244 | 85th |
Division Manufacturing | 757 out of 5,765 | 87th |
Major group Chemicals And Allied Products | 251 out of 2,128 | 88th |
Industry group Drugs | 200 out of 1,817 | 89th |
Industry Pharmaceutical Preparations | 154 out of 1,391 | 89th |
Source: SEC filing on April 19, 2019.
Baum's colleagues
We found four more compensation records of executives who worked with Charles M. Baum at Mirati Therapeutics in 2018.
2018
James Christensen
Mirati Therapeutics
Chief Scientific Officer
2018
Chris LeMasters
Mirati Therapeutics
Executive Vice President and Chief Business Officer
2018
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
2018
Jamie Donadio
Mirati Therapeutics